摘要
新药研究开发是指新药从实验室研究到上市、扩大临床应用的整个过程。国外研制的新药主要集中在抗感染药物、心血管药物、血液系统药物、中枢神经系统药物、抗肿瘤及其辅助用药、生物技术药物和内分泌／代谢药物等。国内上市的新药大多是进口或合资企业的产品,自己生产的医药产品以老药为主,不多的新药也大多是仿制的,中药产业的企业规模小、产品科技含量低,在新药研究开发方面仍然存在经费投入严重不足、产业化条件差以及创新能力差等问题。国内的制药行业应通过战略重组,实现规模经营,在未来激烈的国际竞争中,增强技术开发实力和市场控制能力。
Research and development of new drugs refers to the whole process ranging from experimental study to marketing and clinical application. The research and development of new drugs in industrial countries focuses on drugs for infection, the cardiovascular system, the blood system, the central nervous system and tumors, and on adjuvant drugs, Biotech drugs, endocrinologic and metabolic drugs. At present most domestic new drugs are imported or from joint venture pharmaceutical companies, and most domestic pharmaceutical manufacturers are mainly involved in the production of old drugs. In addition, most domestic new drugs are patent drugs. The disadvantages of the Chinese pharmaceutical industry include small-scale production and low technology content. The main problems in new drug research and development include shortage of finance , poor conditions of industrialization and low ability of innovation. It is necessary and urgent to do our best to enhance the Chinese pharmaceutical industry with respect to technological exploitation and power of market control in the context of international competition through strategic merging and scale management.
出处
《第二军医大学学报》
CAS
CSCD
北大核心
2004年第5期465-468,共4页
Academic Journal of Second Military Medical University
基金
国家自然科学基金(30271180).
